Team

antoine.png

Dr. Antoine Herzog

Chief Executive Officer

weida.png

Dr. Weida Chen

Chief Technology Officer

Precision oncology is revolutionizing cancer care. 

Jiande Zhou

Project Manager Library Preparation

Vivien Riolo

Project Manager CTC Isolation

jiande.png
vivien.png

Key advisors

michael.png
philippe.jpg.png
krisztian.png

Michael Doherty

Prof. Philippe Renaud

Dr. Krisztian Homicsko

Michael Doherty has over two decades of expertise in product development and global regulatory strategy.

Previously, Michael was head of product development and R&D for Foundation Medicine (acquired by Roche in 2018, $5.3 billion valuation), where he led development of the FoundationOne CDx assay, the first FDA-approved broad sequencing panel for oncology.

Before that, Michael spent 15 years at Roche leading the strategic innovation team, which focused on ensuring future sustainability for drug development. He also delivered a world-leading oncology portfolio as the global head of regulatory affairs.

Prof. Philippe Renaud is professor at the Microsystems Laboratory 4 (LMIS4) and the scientific director of the Center of MicroNanoTechnology at EPFL.

Prof. Philippe Renaud is a professor of microengineering focusing on biomedical devices. His expertise lies in the design and fabrication of microfluidics especially for cell manipulation and diagnostics.

Prof. Renaud has shown his passion to transform laboratory discoveries into concrete technologies through several spin-off companies (e.g. Biocartis, Abionic) which are used in clinics worldwide.

Dr. Homicsko works as a Clinic Head in the Department of Oncology of CHUV where he co-heads the Molecular Tumor Board within the Centre for Personalized Oncology of the Department of Oncology.

He has given numerous presentation on personalized oncology and translation oncology at leading international meetings. Dr. Homicsko is part of translational research and advisory team of the European Thoracic Oncology Platform (ETOP) and Primary Invesigator of two translational projects of ETOP clinical trials.

Dr. Homicsko also provided advisory functions and gave presentations to pharmaceutical companies notably to BMS, Amgen, Roche and Novartis.

Supported by

381-3818450_cole-polytechnique-fdrale-de-lausanne-school-of-epfl.png
Universitätsspital_Lausanne_CHUV_logo.svg.png
biopole.jpg
Innosuisse-fr.jpg
venture-kick-logo-vector.png
logo_mc.png
startlab.png
enabled.png
Innovaud -logo-one line-RGB-COLOR-01.png